ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference.
MENLO PARK, Calif. and SINGAPORE, May 31, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Pte Ltd (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference. The conference will be held in-person in New York, NY, June 8 - 10, 2022.
Management will be available for virtual one-on-one meetings throughout the conference.
Fireside Chat details
Date: Wednesday, June 8, 2022
Time: 10:00am ET
Track: 9
Webcast link: Click here to listen in live or via replay
A replay of the presentation will be available for 90 days at the link above and in the News & Events section of ASLAN Pharmaceutical’s Investor Relations website.
Media and IR contacts
| Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: ASLAN@spurwingcomms.com | Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: arr@lifesciadvisors.com |
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and farudodstat (also known as ASLAN003), a potent oral inhibitor of the enzyme, DHODH, in autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.
